Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

PSTI 2.93 -0.04 (-1.35%)
price chart
Insider Buying: Yaky Yanay Acquires 10000 Shares of Pluristem Therapeutics ...
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) COO Yaky Yanay acquired 10,000 shares of the company's stock on the open market in a transaction dated Tuesday, September 16th. The stock was purchased at an average price of $2.85 ...
Jefferies Group Lowers Pluristem Therapeutics Price Target to $3.00 (PSTI)  Ticker Report
Pluristem Therapeutics PT Lowered to $3.00 (PSTI)  Intercooler
Related articles »  
United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's ...
Pluristem Therapeutics Inc. PSTI, -2.54% (tase:PLTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase ...
Phase I Trial of Pluristem's PLX-PAD Cells for Pulmonary Arterial ...  Pulmonary Hypertension News
Related articles »  
Pluristem Therapeutics COO Yaky Yanay Buys 10000 Shares (PSTI)
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) COO Yaky Yanay acquired 10,000 shares of the company's stock on the open market in a transaction dated Tuesday, September 16th. The stock was purchased at an average cost of $2.85 ...
Insider Buying: Zami Aberman Purchases 15000 Shares of Pluristem ...  Intercooler
Investors Are Watching: Discover Financial Services (NYSE:DFS), Nokia ...  WallStreet Scope
Related articles »  
H.C. Wainwright Starts Pluristem Therapeutics (PSTI) at Buy
H.C. Wainwright initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and a price target of $4.00. Analyst Reni Benjamin said, "We are initiating coverage of Pluristem Therapeutics, Inc. with a Buy rating and a 12-month target ...
Pluristem Therapeutics Receives New Coverage from Analysts at HC ...
Pluristem Therapeutics Inc. logo HC Wainwright started coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research report sent to investors on Monday morning.
Pluristem to Deliver Scientific Presentations at 3rd International Placenta ...  CNNMoney
Related articles »  
Trader's Recap: Google Inc (NASDAQ:GOOG), Pluristem Therapeutics ...
HC Wainwright started coverage on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a research report sent to investors on Monday morning.
Pluristem Therapeutics (PSTI) Posts Quarterly Earnings Results, Beats ...  sleekmoney
Pluristem Therapeutics (PSTI) Releases Quarterly Earnings, Beats Estimates ...  Intercooler
Related articles »  
HC Wainwright Initiates Coverage on Pluristem Therapeutics (PSTI)
Pluristem Therapeutics Inc. logo Stock analysts at HC Wainwright began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a report issued on Monday.
Related articles »  
Top News : Nokia Corporation (ADR) (NYSE:NOK), Pluristem Therapeutics ...
On JULY 31, Pluristem Therapeutics Inc (NASDAQ:PSTI) a leading developer of placenta-based cell therapies, announced that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy ...
Pluristem Therapeutics (PSTI) Posts Quarterly Earnings, Beats Estimates By ...
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) posted its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.06, Stock Ratings ...
What's Hot Today: Avago Technologies Limited (NASDAQ:AVGO), General ...  WallStreet Scope
Related articles »  
Morning Buzz: OXiGENE (NASDAQ:OXGN), Pluristem Therapeutics (NASDAQ ...
On 26 AUG OXiGENE, Inc. (NASDAQ:OXGN) announced that David Chaplin, Ph.D., CEO, will present a corporate overview at the Rodman and Renshaw Annual Global Investment conference on Tuesday, September 9, 2014 at 1:15 p.m.